The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States.
Roman Casciano
Consultant or Advisory Role - Novartis
Maruit Chulikavit
Consultant or Advisory Role - Novartis
Allison Perrin
Consultant or Advisory Role - Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Joseph Babigumira
Consultant or Advisory Role - Novartis
Louis P Garrison
Consultant or Advisory Role - Novartis